Table 2.
Grade 3 and 4 adverse events
| Adverse event | FOLFIRI plus panitumumab (n = 61) | FOLFIRI plus bevacizumab (n = 60) | ||
|---|---|---|---|---|
| ≥Grade 3 | ≥Grade 3 | |||
| n | % | n | % | |
| Any adverse events | 54 | 88.5 | 40 | 66.7 |
| Neutropenia | 30 | 49.2 | 28 | 46.7 |
| Stomatitis | 13 | 21.3 | 4 | 6.7 |
| Leucopenia | 11 | 18.0 | 17 | 28.3 |
| Acneiform rash | 10 | 16.4 | 0 | 0.0 |
| Hypomagnesemia | 7 | 11.5 | 0 | 0.0 |
| Anorexia | 6 | 9.8 | 7 | 11.7 |
| Proteinuria | 6 | 9.8 | 2 | 3.3 |
| Non‐neutropenic infection | 5 | 8.2 | 3 | 5.0 |
| Dry skin | 5 | 8.2 | 0 | 0.0 |
| Paronychia | 4 | 6.6 | 0 | 0.0 |
| Thromboembolic events | 4 | 6.6 | 0 | 0.0 |
| Anemia | 3 | 4.9 | 7 | 11.7 |
| Diarrhea | 3 | 4.9 | 4 | 6.7 |
| Nausea | 2 | 3.3 | 3 | 5.0 |
| Vomiting | 2 | 3.3 | 3 | 5.0 |
| Febrile neutropenia | 2 | 3.3 | 3 | 5.0 |
| Fatigue | 1 | 1.6 | 5 | 8.3 |
| Thrombocytopenia | 1 | 1.6 | 3 | 5.0 |
| Any bleeding | 1 | 1.6 | 2 | 3.3 |
| Pneumonitis | 1 | 1.6 | 1 | 1.7 |
| Gastrointestinal perforation | 0 | 0.0 | 1 | 1.7 |
FOLFIRI, fluorouracil, leucovorin, and irinotecan.